6 ms·
How to Slash the Cost of Drug Development
- refurb 10y agoAnd it has put another 26 drugs into development. It has done this with US$290 million—about one-quarter of what a typical pharmaceutical company would spend to develop just one drug They are comparing two different things with this statement. You can't compare "bringing something into development" and bringing it to market. Hell, if I move some crap drug into phase one i've "brought it into development". It means nothing. Also, the one example of a marketed drug they successfully brought to market was a combination of two already approved drugs. The risks are much lower when you don't have to worry about toxicity and ADME. I'll give them credit for working on a noble cause, but I've seen nothing to suggest they've fixed the challenges of R&D.
- sbierwagen 10y agoUnlikely. It has done this with US$290 million—about one-quarter of what a typical pharmaceutical company would spend to develop just one drug. The model for its success is the product development partnership (PDP), a style of non-profit organization that became popular in the early 2000s. PDPs keep costs down through collaboration—with universities, governments and the pharmaceutical industry. So, was the $290 million the total amount for all 26 trials? Or did the collaborators kick in money? Because otherwise this is like claiming you've found a way to buy a new Tesla for $1000-- as long as your parents pay the other $69,000! Drug development from scratch is arduous and expensive. It begins with experiments on hundreds of thousands of chemicals in the lab, looking for one that kills a pathogen without harming the host. The article does not go out of its way to mention that this isn't the expensive and arduous part. The clinical trials are what's expensive, since you have to pay thousands of people, who have the disease you're targeting, to take your experimental drug. In many cases, they have to take your drug instead of a drug that's known to work. And you have to follow these people for years, just in case they don't all suddenly get liver cancer and die a year after they stop taking your drug. (Something like this cost Merck $4.85 billion dollars in 2004: https://en.wikipedia.org/wiki/Rofecoxib https://en.wikipedia.org/wiki/Rofecoxib ) The final trials on fexinidazole conclude this year, and Wourgaft is hopeful that the data will earn regulators' stamp of approval. The project has so far cost the DNDi about $45 million—and it stands to help 21 million people at risk of the disease in Africa. Which regulators? There is a rather huge difference between the FDA and the Central African Republic's FDA-equivalent. Is this how they're saving money on clinical trials, by running clinical trials on Africans, and only getting regulatory approval from African states?
- daxfohl 10y agoRunning unregulated clinical trials in impoverished nations is demonized and illegal when done by big pharma, but championed when done by some little company "trying to make a difference". I like the ideal but so much of this seems like marketing. Granted, motivation makes a big difference here. However it's often hard to tell profit motive from innate motive, especially in a legal context. What starts off as innate can quickly become profit-oriented (or even worse "I told you so"-oriented) behind closed doors when stuff hits the fan.
- jedmeyers 10y ago> I like the ideal but so much of this seems like marketing. Running unregulated clinical trials in impoverished nations makes a corporate comeback.
- sandworm101 10y ago>> unregulated clinical trials in impoverished nations is demonized It is, but regulated trials in such countries have real scientific advantages. The average US patient (older, overweight, probably diabetic) swims in a cocktail of drugs ranging from painkillers[1] to cholesterol reducers. By some estimates 60% of American adults are on one or more prescription drugs, a percentage that no doubt climbs with age. That makes them difficult guinea pigs for the study of new treatments. But the average African cannot afford such cocktails and so is most likely clean of other drugs. Costs and poverty aside, if you are looking for a drug-free study population, Africa is easier than the west. [1] "In 2010, enough prescription painkillers were prescribed to medicate every american adult every 4 hours for 1 month." https://www.drugabuse.gov/related-topics/trends-statistics/infographics/popping-pills-prescription-drug-abuse-in-america https://www.drugabuse.gov/related-topics/trends-statistics/i...
- arkades 10y agoThat's the opposite of a real scientific advantage. Most drug effectiveness is related to the population in which it is deployed, based on their combination of unique risk factors and etiologies. Socioeconomic factors (and I mean that in its accurate usage, not just a short-hand for "income") are a huge example: they're one of the biggest predictors of health outcomes and responsiveness to various treatments, and using a population with wildly different SES factors fundamentally kills the trial. A sample population which accurately reflects the general population in which a drug is to be deployed is assessed, in clinical trials, as something known as "external validity" (as opposed to "internal validity", which is just whether the experiment is properly designed to test its stated hypothesis). tl;dr apparent drug effects in Africans are not useful indicators of drug effects in Americans, particularly if your premise is "those drugs have different outcomes in Americans."
- mrleinad 10y agoBig pharmas don't set the price for drugs based on their cost. They base the price on what people on different regions can pay, thus maximizing their profit. Cost is not a variable for the price, how much money people have in that sector is really the basis of it.
- WalterBright 10y agoCompanies ignore costs at their peril. In fact, the usual reason for corporate failure is their costs exceeded their revenue. Pricing can be very complex topics, people have written whole books about it, like the classic "Strategy and Tactics of Pricing" by Nagle.
- hga 10y agoThat's the most very basic principle of marketing and sales, so why "big pharmas" wouldn't engage it would be curious. In field where marketing and pricing are much less understood, like ours, the trick is that after you establish acceptable pricing for your widgets, you then compare that to all your production, etc. costs to to see if you should keep selling them etc Note that in many "regions" "big pharma" negotiates the price with a penny punching government Note also some drugs are inherently expensive to produce, I'm thinking one anti-HIV one that had the usual suspects screaming, but it has 3 chiral centers (ouch!; for a layman's analogy illustration, Derek Lowe wrote a good one using ballons...).
- hx87 10y ago> Note that in many "regions" "big pharma" negotiates the price with a penny punching government That's one of the reasons why drugs are so expensive in the US--we are one of the few countries to not have government negotiating our side, so pharmaceutical companies have to make their profit here.
- hga 10y agoIndeed, and if we "fix" that, well, I satisfy myself with the thought that many of the people supporting that policy, and/or their loved ones, will needlessly suffer and/or prematurely die because they stopped the development of a drug that would have saved them.
- dannylandau 10y agoIf you could run a drug development company like you do a start-up, then you could probably speed up drug development 1000x fold. Of course, still need to have some safety mechanisms in place to prevent serious injury/death, but there is a gigantic room for improvement that will benefit humankind.
- daxfohl 10y agoUnfortunately the only ones running drug development companies like startups have been snake oil salesmen since time began. The only comfort lies in that big pharma is only ~ 1/2 snake oil.
- dalke 10y agoAnd the many failed attempts to do drug discovery have earned such optimistic views the sobriquet "the Andy Grove Fallacy." http://blogs.sciencemag.org/pipeline/archives/2015/04/02/silicon_valley_sunglasses http://blogs.sciencemag.org/pipeline/archives/2015/04/02/sil... and https://www.quora.com/What-is-the-Andy-Grove-fallacy https://www.quora.com/What-is-the-Andy-Grove-fallacy for details.
- vibrio 10y agoIsn't a significant proprtion of the products Big Pharma sells were developed by start ups? based on my undestanding it is hard to claim that Pharma like Sanofi and Pfizer have good track records at internally discovering and bringing drugs to market despite spending billions annually on R&D.
- evgen 10y agoAt this point big pharma companies are more like Google or Facebook -- all real innovation comes from buying up the little start-ups that actually create something new and using your existing channel to customers to hone the product and crank up distribution.
- mtgx 10y agoSo what you're asking for is the "Uber of pharma".
- DanielBMarkham 10y agoI was uncomfortable reading this. I kept waiting for some assurance from the writer that they understood the complexity of the drug manufacturing landscape. Instead I got a blanket statement that the "expensive drug" thing is a myth, and a pro forma contrarian view 80% of the way down the page -- which was quickly shot down. (By the way, this story format is getting a little old. The writer obvious has a pitch to make. They make the pitch by talking to selected subjects and using their quotes. Then, in order to somehow assure the reader of balance, they bring in a fall guy about 80% of the way in to say something cranky. Then they dismiss it. It's okay in argumentation, I guess, but really should be rare in straight reporting.) Note that I'm not saying there isn't something cool here. Beats me. I read the article and have no more of an understanding about drug development than when I began. This felt like one of those articles where an editor runs into a booster at a social event and is told how really cool X is. They get excited. So they tell a writer to go write a story telling folks how really cool X is. Mission accomplished. But not such a good article, sadly.
- randcraw 10y agoDaniel, I do work in drug development, and I have no better idea than you how this "new and better way" to make drugs will really work. The author mentions repeatedly that DNDi got reduced cost access to both high throughput screening, clinical trials, and drug regulation, so they can develop a drug for less cost. No surprise, but how is this a sustainable model for developing most new drugs? What processes have they improved to save money/time that is not dependent on freebies from generous for-profit drug corporations, universities, and governments? Somehow I missed that part. Personally, I'd dearly love to reduce the cost of drug development and prices. But until DNDi pays the full cost for all of the reagents, processes, and rules in their drug development process, they have no business claiming to have cured the ills that bedevil big pharma. No business at all.
- msandford 10y agoWhat I read is that they aren't looking for a multi-billion dollar profit. Which means that they don't have to work on a drug that they can sell to everyone. Which means that they can focus on neglected areas of medicine for which the existing treatments are non-existent or terrible. It's the difference between "proving" that changing a button color at Amazon makes people buy 1% more stuff (worth billions, probably) and "proving" it at a start-up. The start-up won't care about 1% more, but if you can triple sales, awesome! Even though tripling sales at a start-up might only be worth $500k, not billions. When you're making HUGE inroads on efficacy it's much, much easier to demonstrate and you don't need thousands or tens of thousands of patients in the trial in order to get a statistically significant result.
- pella 10y agorelated: "Open Source Drug Discovery" - "collaborative drug discovery platform for neglected tropical diseases like leishmaniasis, which draw limited attention of research, based pharmaceutical enterprises" https://en.wikipedia.org/wiki/Open_Source_Drug_Discovery https://en.wikipedia.org/wiki/Open_Source_Drug_Discovery --or -- "Crowdsourcing in pharma: a strategic framework" http://dx.doi.org/10.1016/j.drudis.2015.01.011 http://dx.doi.org/10.1016/j.drudis.2015.01.011 pdf: http://csmres.co.uk/cs.public.upd/article-downloads/Crowdsourcing-in-pharma.pdf http://csmres.co.uk/cs.public.upd/article-downloads/Crowdsou...